Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design
about
Interaction of the antimicrobial peptide polymyxin B1 with both membranes of E. coli: a molecular dynamics studyUptake of polymyxin B into renal cellsLycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway.Imaging the distribution of polymyxins in the kidneyMajor pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells.Kidney injury associated with telavancin dosing regimen in an animal modelPreliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicityPolymyxin B Nephrotoxicity: From Organ to Cell Damage.Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.Pharmacokinetics and renal disposition of polymyxin B in an animal model.Characterization of Polymyxin B Biodistribution and Disposition in an Animal ModelMulticenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiEvaluation of Risk Factors for Intravenous Colistin Use-related NephrotoxicityPolymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells.In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.Speculative strategies for new antibacterials: all roads should not lead to Rome.Adverse reactions associated with systemic polymyxin therapy.Strategies for the safe use of colistin.Polymyxin B versus colistin: an update.Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective.Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity.Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure.Synergistic effect of membrane-active peptides polymyxin B and gramicidin S on multidrug-resistant strains and biofilms of Pseudomonas aeruginosa.Risk factors for nephrotoxicity onset associated with polymyxin B therapy.Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.Application of emerging biomarkers of acute kidney injury in development of kidney-sparing polypeptide-based antibiotics.Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress.Identification of São Paulo metallo-beta-lactamase-1-producing Pseudomonas aeruginosa in the Central-West region of Brazil: a case study.Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity.Fighting biofilms with lantibiotics and other groups of bacteriocins.
P2860
Q28546494-B99ED921-C3D9-4C8C-B8AB-6443FB8B0581Q33798384-D58EEA79-9881-466D-9775-1364C05E709BQ34922961-89367BB0-37BA-4317-95D8-606BD0EC6852Q35056878-18DC6201-3C58-42A2-A265-232AB5444BD6Q35168993-E5779821-B3D6-48E5-B436-572CB6C3A8F4Q35385051-3D5F59FD-17A5-4F08-982F-4D1CF69EF3E8Q35607925-93B7DEFE-C557-49EF-9807-53CF5EA3BF16Q36105647-55E0CBAF-3A11-4399-991C-D4887046286AQ36290642-102ACD85-D3BA-46A0-B1F3-C2D4DA84C6AEQ36364194-1D6F79A6-8584-41C4-8F6C-B127C42AD3F2Q36571918-87487D18-B5B2-42FC-BAD9-DBAC9998D177Q36730174-43AC8DAF-7D2A-4197-9F00-89E5AF85D4EBQ37023206-ED6B74FD-6452-448A-9298-1E76F555A635Q37053617-4DA85D43-5069-4553-86E4-D87FD51CB943Q37124019-58C22CAD-6EE1-42C9-AEF3-640E568EFB6DQ37712983-5DB9E670-DA7B-47A8-84C4-4941CD150404Q38101243-4F9E4A56-67CC-451C-87F1-36ACC9682338Q38255373-C78A0C4E-3FBE-4ED8-994E-4700F55DE17EQ38548658-BF7D2369-CB1B-4A2C-B0F9-1D8FF020E6F7Q38613051-5DE8FA7D-1017-42DF-8843-34B055DA2510Q39043757-9735389D-1F9B-4B21-B5AE-95260C5DD4AFQ39433962-55D05DE7-8BC8-4D84-B50B-60BA1D5CADCAQ40368623-8A9B1953-66B3-45BD-97D3-81087A35819DQ40719307-4A80BF45-D748-4D7D-A4E4-E940B9C303C2Q40962296-8A706CE1-4C14-4703-98BD-338520F1FEAFQ41159517-4970BEE8-28E2-4F1A-AA09-496A1BF2D1F8Q41477519-F1448663-33AC-4F94-8324-D90EE72CDA9DQ41532045-7BD9D25E-5329-4C40-B7F1-9D5C987EA4B8Q46127968-B2BAEA2A-CF41-4FDB-83FE-685A6BEA813AQ47735607-E7C6DEC2-7C86-416C-8016-4A3A1145F45AQ48054597-7071FB43-F40B-4BF4-8B92-3EB0361DCFFEQ55098021-B023D4E8-BF44-45F6-8FC6-AA6B9C0467BFQ55223927-BAE96602-50A6-40B0-A31C-4686A7D90661
P2860
Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Characterization of polymyxin ...... ions for dosing regimen design
@ast
Characterization of polymyxin ...... ions for dosing regimen design
@en
type
label
Characterization of polymyxin ...... ions for dosing regimen design
@ast
Characterization of polymyxin ...... ions for dosing regimen design
@en
prefLabel
Characterization of polymyxin ...... ions for dosing regimen design
@ast
Characterization of polymyxin ...... ions for dosing regimen design
@en
P2093
P2860
P356
P1476
Characterization of polymyxin ...... ions for dosing regimen design
@en
P2093
Kamilia Abdelraouf
Kirk H Braggs
Luan D Truong
Taijun Yin
Vincent H Tam
P2860
P304
P356
10.1128/AAC.00280-12
P407
P577
2012-06-11T00:00:00Z